Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

NCT06418061 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable
Locally Advanced or Metastatic Solid Tumors

Interventions

DRUG: IBI3005

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.